Funding source: NIH
Funding source: National Heart, Lung, and Blood Institute
Award Identifier / Grant number: HL-18-023
-
Research funding: This study was supported by the NIH/NHLBI Stimulating Access to Research in Residency (StARR) R38 Program.
-
Author contributions: P.W.M., M.C.K., S.D., D.L.M., and A.D. designed the study. M.C.K. performed the experiments. S.D., M.A.V.W., D.L.M., and A.D. interpreted MASS-FIX and IFE results. P.W.M. wrote the manuscript. M.A.G., S.K.K., and M.L.Q. reviewed the manuscript. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: We declare one competing interest on behalf of authors Drs. David Murray and Surendra Dasari, who have patent rights on MASS-FIX technology and potential royalties from its use.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: This study was approved by the Mayo Clinic Institutional Review Board.
References
1. van de Donk, NW, Otten, HG, El Haddad, O, Axel, A, Sasser, AK, Croockewit, S, et al.. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med 2016;54:1105–9. https://doi.org/10.1515/cclm-2015-0888.Search in Google Scholar
2. Milani, P, Murray, DL, Barnidge, DR, Kohlhagen, MC, Mills, JR, Merlini, G, et al.. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol 2017;92:772–9. https://doi.org/10.1002/ajh.24772.Search in Google Scholar
3. Mills, JR, Kohlhagen, MC, Willrich, MAV, Kourelis, T, Dispenzieri, A, Murray, DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood 2018;132:670–2. https://doi.org/10.1182/blood-2018-05-848986.Search in Google Scholar
4. Tai, YT, Mayes, PA, Acharya, C, Zhong, MY, Cea, M, Cagnetta, A, et al.. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014;123:3128–38. https://doi.org/10.1182/blood-2013-10-535088.Search in Google Scholar
5. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma [news release]. U.S. Food and Drug Administration. Silver Spring, MD: US FDA; 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma [Accessed 26 Jan 2020].Search in Google Scholar
6. Lonial, S, Lee, HC, Badros, A, Trudel, S, Nooka, AK, Chari, A, et al.. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207–21. https://doi.org/10.1016/s1470-2045(19)30788-0.Search in Google Scholar
7. Kohlhagen, MC, Barnidge, DR, Mills, JR, Stoner, J, Gurtner, KM, Liptac, AM, et al.. Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016;62:1345–52. https://doi.org/10.1373/clinchem.2015.253781.Search in Google Scholar PubMed
8. Belantamab mafodotin. Prescribing information. GlaxoSmithKline. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf [Accessed 26 Jan 2020].Search in Google Scholar
9. Clemens, PL, Yan, X, Lokhorst, HM, Lonial, S, Losic, N, Khan, I, et al.. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet 2017;56:915–24. https://doi.org/10.1007/s40262-016-0477-1.Search in Google Scholar PubMed PubMed Central
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2021-0326).
© 2021 Walter de Gruyter GmbH, Berlin/Boston
